Akums Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 8, 2026
- Posted by: Harsh Piplani
- Category: Results
Akums Drugs share price Rs 736.60 on 8 September 2026, down 2.39%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 100.98 crore. Q2 FY26 base a profit of Rs 42.70 crore.
Quick Answer
The Akums Drugs Q2 results date for FY27 is not confirmed, and Akums Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,049.90 crore in revenue and a profit of Rs 42.70 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Akums Drugs Q2 results FY27 announcement is the next scheduled earnings event for Akums Drugs & Pharmaceuticals Ltd., India’s largest contract development and manufacturing organisation for pharmaceutical formulations, alongside its own branded and generic products. The stock traded at Rs 736.60 on the NSE on 8 September 2026, down 2.39% from the previous close of Rs 754.65, about 7.5% below its 52-week high of Rs 796.55 and 80.0% above its 52-week low of Rs 409.30.
What makes the Akums Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,049.90 crore of revenue and a profit of Rs 42.70 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,197.01 crore and a profit of Rs 100.98 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Akums Drugs Q2 Results FY27 Date?
The Akums Drugs Q2 results date for FY27 is not confirmed. As of 8 September 2026, Akums Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Akums Drugs Q2 results date becomes public through that filing rather than through any advance announcement.
The Akums Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Akums Drugs.
Akums Drugs Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Akums Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Akums Drugs. The Akums Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is the margin expansion. Operating margin climbed to 17.58% in Q1 FY27 from 12.47% in the September 2025 quarter, which is why profit more than doubled to Rs 100.98 crore from Rs 42.70 crore on almost unchanged revenue.
The second is contract manufacturing volume. Akums Drugs manufactures for a large number of Indian pharmaceutical brands, so its revenue tracks its customers’ order patterns rather than end-market prescriptions directly.
The third is the September 2025 base of Rs 42.70 crore in profit, the weakest of the last five quarters. A soft base flatters the year-on-year percentage, so the rupee figure is the better measure of progress.
Check Akums Drugs & Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener
Akums Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Akums Drugs & Pharmaceuticals Ltd. reported revenue of Rs 1,197.01 crore in Q1 FY27, up 13.92% from Rs 1,050.76 crore in Q1 FY26, and a profit of Rs 100.98 crore at the net level, up 56.10% from Rs 64.69 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 0.32% over the March 2026 quarter figure of Rs 1,193.17 crore, and net profit was up 24.15% from Rs 81.34 crore in Q4 FY26. Operating margin stood at 17.58% in Q1 FY27 against 12.47% in the September 2025 quarter, which is the comparison the Akums Drugs Q2 results print will be read against.
Q2 FY26 Base: The Comparison Akums Drugs Q2 Results FY27 Must Beat
Akums Drugs & Pharmaceuticals Ltd. reported revenue of Rs 1,049.90 crore and a profit of Rs 42.70 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Akums Drugs Q2 results preview.
Net profit in that base quarter was below the Rs 100.98 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,049.90 crore sits below the Rs 1,197.01 crore of the June 2026 quarter, which frames how much sequential movement the Akums Drugs Q2 results print needs to show growth.
Akums Drugs Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 1,049.90 | 42.70 |
| Q3 FY26 (Dec 2025) | 1,193.92 | 67.67 |
| Q4 FY26 (Mar 2026) | 1,193.17 | 81.34 |
| Q1 FY27 (Jun 2026) | 1,197.01 | 100.98 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Akums Drugs Q2 results preview uses.
Revenue across those four quarters ranged from Rs 1,049.90 crore to Rs 1,197.01 crore, and net profit from Rs 42.70 crore to Rs 100.98 crore. That spread is the honest context for the Akums Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Akums Drugs Q2 Results FY27
The Akums Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Akums Drugs has already reported.
Contract Manufacturing Utilisation
Plant utilisation is the main margin lever for a contract manufacturer. Revenue has been broadly flat near Rs 1,200 crore for three quarters while margin rose, which points to better mix or pricing rather than volume.
Customer Concentration
Serving many pharmaceutical brands spreads risk, but a change in terms with any large customer moves both volume and margin. Any commentary on the customer base is worth reading alongside the numbers.
Valuation Against a Recovering Return
The stock trades at a price-to-earnings ratio of 40.60 against a sector average of 37.70 on a return on equity of 7.70%. It has risen well above its 200-day average of Rs 544.38 as the margin recovery has played out.
Akums Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print
Akums Drugs share price today is Rs 736.60 on the NSE, down Rs 18.05 or 2.39% from the previous close of Rs 754.65 on 8 September 2026, ahead of the Akums Drugs Q2 results announcement.
| Metric | Value (8 September 2026) |
|---|---|
| NSE Symbol | AKUMS |
| Current Market Price | Rs 736.60 |
| 52-Week High | Rs 796.55 |
| 52-Week Low | Rs 409.30 |
| Market Capitalisation | Rs 11,886 crore |
| PE Ratio | 40.60 |
| Sector PE | 37.70 |
| PB Ratio | 3.59 |
| EPS (TTM) | Rs 18.60 |
| Book Value per Share | Rs 210.57 |
| Debt to Equity | 0.05 |
| Return on Equity | 7.70% |
| 50-Day Moving Average | Rs 707.63 |
| 200-Day Moving Average | Rs 544.38 |
| RSI (14) | 45.79 |
The stock trades above both its 50-day average of Rs 707.63 and its 200-day average of Rs 544.38, with a 14-day RSI of 45.79. None of this is a view on where the shares go once the Akums Drugs Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Akums Drugs & Pharmaceuticals Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Akums Drugs Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Akums Drugs Q2 results print in proportion.
- Revenue against the Rs 1,049.90 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 42.70 crore in that same quarter
- Operating margin against 17.58% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Akums Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Akums Drugs Q2 Results FY27
The Akums Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Akums Drugs & Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Akums Drugs Q2 results FY27 print faces a base of Rs 1,049.90 crore in revenue and a profit of Rs 42.70 crore, with the most recent quarter having delivered Rs 1,197.01 crore and a profit of Rs 100.98 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Akums Drugs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Akums Drugs Q2 Results FY27
What is the Akums Drugs Q2 results date for FY27?
Ans. The Akums Drugs Q2 results date for FY27 is not confirmed. Akums Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Akums Drugs Q2 results 2026 cover?
Ans. The Akums Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Akums Drugs & Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Akums Drugs Q2 results filing also carries the notes to the accounts.
What were the Akums Drugs Q1 FY27 results?
Ans. Akums Drugs & Pharmaceuticals Ltd. reported revenue of Rs 1,197.01 crore in Q1 FY27 and a profit of Rs 100.98 crore at the net level. Revenue was up 13.92% versus Q1 FY26 and net profit was up 56.10% from Rs 64.69 crore in Q1 FY26.
What were Akums Drugs Q2 FY26 results in the September 2025 quarter?
Ans. Akums Drugs & Pharmaceuticals Ltd. reported revenue of Rs 1,049.90 crore and a profit of Rs 42.70 crore in Q2 FY26. Operating margin was 12.47%. Those figures form the base for the Akums Drugs Q2 results FY27 comparison.
What are the main Akums Drugs Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Akums Drugs Q2 results expectations centre on revenue against the Rs 1,049.90 crore base, net profit against a profit of Rs 42.70 crore, operating margin against 17.58% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Akums Drugs share price today ahead of the Q2 earnings?
Ans. Akums Drugs share price is Rs 736.60 on the NSE as of 8 September 2026, down 2.39% from Rs 754.65. The stock is about 7.5% below its 52-week high of Rs 796.55 and 80.0% above its 52-week low of Rs 409.30, at a market capitalisation of Rs 11,886 crore.
Is Akums Drugs a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Akums Drugs & Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 3.59 with a return on equity of 7.70%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
